KR20130128308A - 이행 소포체 ａｔｐ아제의 저해를 위한 방법 및 조성물 - Google Patents

이행 소포체 ａｔｐ아제의 저해를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20130128308A
KR20130128308A KR1020127032164A KR20127032164A KR20130128308A KR 20130128308 A KR20130128308 A KR 20130128308A KR 1020127032164 A KR1020127032164 A KR 1020127032164A KR 20127032164 A KR20127032164 A KR 20127032164A KR 20130128308 A KR20130128308 A KR 20130128308A
Authority
KR
South Korea
Prior art keywords
formula
groups described
methyl
compounds
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127032164A
Other languages
English (en)
Korean (ko)
Inventor
레이몬드 제이. 데샤이스
츠이-펜 초우
프랭크 제이. 스코에넨
켈린 리
케빈 제이. 프란코프스키
제프리 오브
사뮤엘 더블유. 게리츠
한-지에 조우
Original Assignee
캘리포니아 인스티튜트 오브 테크놀로지
더 유니버시티 오브 캔사스
클리브 바이오사이언스 인코포레이티드 (클리브)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캘리포니아 인스티튜트 오브 테크놀로지, 더 유니버시티 오브 캔사스, 클리브 바이오사이언스 인코포레이티드 (클리브) filed Critical 캘리포니아 인스티튜트 오브 테크놀로지
Publication of KR20130128308A publication Critical patent/KR20130128308A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020127032164A 2010-05-07 2011-05-06 이행 소포체 ａｔｐ아제의 저해를 위한 방법 및 조성물 Withdrawn KR20130128308A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33266710P 2010-05-07 2010-05-07
US61/332,667 2010-05-07
PCT/US2011/035654 WO2011140527A2 (en) 2010-05-07 2011-05-06 Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase

Publications (1)

Publication Number Publication Date
KR20130128308A true KR20130128308A (ko) 2013-11-26

Family

ID=44904519

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127032164A Withdrawn KR20130128308A (ko) 2010-05-07 2011-05-06 이행 소포체 ａｔｐ아제의 저해를 위한 방법 및 조성물

Country Status (8)

Country Link
US (1) US8865708B2 (enExample)
EP (1) EP2566480A4 (enExample)
JP (1) JP2013530942A (enExample)
KR (1) KR20130128308A (enExample)
CN (1) CN103068393A (enExample)
AU (1) AU2011249859B2 (enExample)
CA (1) CA2798698A1 (enExample)
WO (1) WO2011140527A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140527A2 (en) 2010-05-07 2011-11-10 California Institute Of Technology And The University Of Kansas Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase
US8906918B1 (en) * 2012-03-23 2014-12-09 University Of South Florida (A Florida Non-Profit Corporation) Compositions, methods of use, and methods of treatment
KR101862912B1 (ko) 2012-07-20 2018-05-30 클리브 바이오사이언스 인코포레이티드 (클리브) p97 복합체의 저해제로서의 축합된 피리미딘
EP2938610A2 (en) * 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
JP6441334B2 (ja) 2013-07-16 2018-12-19 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 除草性アジン
DE102013110714A1 (de) * 2013-09-27 2015-04-02 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung
ES2739435T3 (es) 2013-10-18 2020-01-31 Univ Indiana Res & Tech Corp Efectores del ensamblaje viral de la hepatitis B
US9868722B2 (en) 2013-12-10 2018-01-16 Cleave Biosciences, Inc. Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex
WO2015109285A1 (en) * 2014-01-20 2015-07-23 Cleave Biosciences, Inc. FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
WO2015155272A1 (en) 2014-04-11 2015-10-15 Basf Se Diaminotriazine derivatives as herbicides
BR112016022782B1 (pt) 2014-04-23 2020-01-28 Basf Se composto de diaminotriazina, composição agroquímica e uso de um composto
US10029992B2 (en) 2014-04-23 2018-07-24 Basf Se Diaminotriazine compounds and their use as herbicides
CN107922377A (zh) 2015-04-17 2018-04-17 美国印第安纳大学研究和技术公司 乙肝病毒组装效应子
CN106518849B (zh) * 2016-10-27 2019-08-16 上海人类基因组研究中心 喹唑啉类化合物及其制备方法和用途
US20230096028A1 (en) * 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP4617262A1 (en) * 2022-11-07 2025-09-17 Kyoto University Nitrogen-containing heterocyclic compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014716A1 (en) * 1991-02-20 1992-09-03 Pfizer Inc. 2,4-diaminoquinazolines derivatives for enhancing antitumor activity
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003255482A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity
WO2006105056A2 (en) * 2005-03-28 2006-10-05 Fmc Corporation Insecticidal 2,4-diaminoquinazolines and related derivatives
WO2007041282A2 (en) * 2005-09-29 2007-04-12 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US20100317607A1 (en) * 2007-06-27 2010-12-16 Infectious Disease Research Institute Use of compounds for preparing anti-tuberculosis agents
WO2009011910A2 (en) * 2007-07-18 2009-01-22 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Serices Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
US9089572B2 (en) * 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
WO2010003908A1 (en) * 2008-07-08 2010-01-14 Jakobsson, Andreas Screening assay for compounds targeting the p97 aaa-atpase complex in the ubiquitin proteasome system.
WO2011140527A2 (en) 2010-05-07 2011-11-10 California Institute Of Technology And The University Of Kansas Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase

Also Published As

Publication number Publication date
AU2011249859B2 (en) 2014-07-03
CN103068393A (zh) 2013-04-24
WO2011140527A3 (en) 2012-03-29
AU2011249859A1 (en) 2012-12-20
US20110288082A1 (en) 2011-11-24
EP2566480A2 (en) 2013-03-13
JP2013530942A (ja) 2013-08-01
CA2798698A1 (en) 2011-11-10
US8865708B2 (en) 2014-10-21
EP2566480A4 (en) 2014-03-19
WO2011140527A2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
KR20130128308A (ko) 이행 소포체 ａｔｐ아제의 저해를 위한 방법 및 조성물
EP2809324B1 (en) Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer
CA2824760C (en) Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
US10905665B2 (en) Chemical modulators of signaling pathways and therapeutic use
JP6140083B2 (ja) 三環式ジャイレース阻害薬
EP4098653A1 (en) Pharmaceutical use of aldehyde-based compound
AU2020356793B2 (en) PH/glutathione-responsive β-carbolines/cycloketene derivatives and their preparation and application
KR101718596B1 (ko) 티에닐[3,2-d]피리미딘-4-온 화합물, 그 제조방법, 약물조성물 및 용도
EP2906564B1 (en) Treating brain cancer using agelastatin a (aa) and analogues thereof
JP2013532657A (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
CN106957315B (zh) N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
US20220401419A1 (en) Hydrogen peroxide-responsive keap1-nrf2 ppi inhibitor prodrug, and preparation method therefor
US11987579B2 (en) Niclosamide analogues and therapeutic use thereof
AU3476999A (en) Methods for inhibiting mrp1
CN116768903B (zh) 一种吡咯并嘧啶衍生物及其制备方法、药物组合物和应用
WO2020210662A1 (en) Small molecules for cancer therapy that reduce the expression of transcription factors klf5 and egr-1
WO2008052352A1 (en) Substituted quinone indoleamine 2,3-dioxygenase (ido) inhibitors and syntheses and uses therefor
EP1301518A1 (en) Tricyclic compounds as mrp1-inhibitors
EP2865680A1 (en) Xanthine derivative
CN103906751A (zh) 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
WO2021113743A1 (en) Small molecule rpn13 inhibitors with antitumor properties
CN118791500B (zh) 7-氧杂双环[2.2.1]庚烷-2,3-二羧酸类衍生物及其制备方法和应用
WO2015069766A1 (en) Dupa-indenoisoquinoline conjugates
WO2013055771A1 (en) Thioxothiazolidinone derivatives useful as inhibitors of tdp1
CN118307564A (zh) 一种含氮杂环化合物及其制备方法与应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid